Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid.
van der Sluis K, van Sandick JW, Vollebergh MA, van Dieren JM, Hugen N, Hartemink KJ, Veenhof AAFA, Verhoeven E, van den Berg JG, Snaebjornsson P, Noe M, van Wezel T, Boelens MC, Kodach LL. van der Sluis K, et al. Among authors: vollebergh ma. Oncogene. 2024 Apr 23. doi: 10.1038/s41388-024-03034-z. Online ahead of print. Oncogene. 2024. PMID: 38654110
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M. Verschoor YL, et al. Among authors: vollebergh ma. Nat Med. 2024 May;30(5):1499. doi: 10.1038/s41591-024-02898-8. Nat Med. 2024. PMID: 38448792 Free PMC article. No abstract available.
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M. Verschoor YL, et al. Among authors: vollebergh ma. Nat Med. 2024 Feb;30(2):519-530. doi: 10.1038/s41591-023-02758-x. Epub 2024 Jan 8. Nat Med. 2024. PMID: 38191613 Free PMC article. Clinical Trial.
Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.
Verbeek JGE, van der Sluis K, Vollebergh MA, van Sandick JW, van Harten WH, Retèl VP. Verbeek JGE, et al. Among authors: vollebergh ma. Pharmacoecon Open. 2024 Jan;8(1):119-131. doi: 10.1007/s41669-023-00454-7. Epub 2023 Nov 30. Pharmacoecon Open. 2024. PMID: 38032438 Free PMC article.
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Rozeman EA, Versluis JM, Sikorska K, Hoefsmit EP, Dimitriadis P, Rao D, Lacroix R, Grijpink-Ongering LG, Lopez-Yurda M, Heeres BC, van de Wiel BA, Flohil C, Sari A, Heijmink SWTPJ, van den Broek D, Broeks A, de Groot JWB, Vollebergh MA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU. Rozeman EA, et al. Among authors: vollebergh ma. J Immunother Cancer. 2023 Jul;11(7):e006821. doi: 10.1136/jitc-2023-006821. J Immunother Cancer. 2023. PMID: 37479483 Free PMC article. Clinical Trial.
Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ, Samsom KG, Snaebjornsson P, Battaglia T, Bosch LJW, Lalezari F, Priestley P, Shale C, van den Broek AJ, Jacobs N, Roepman P, van der Hoeven JJM, Steeghs N, Vollebergh MA, Marchetti S, Cuppen E, Meijer GA, Voest EE, Monkhorst K. Schipper LJ, et al. Among authors: vollebergh ma. ESMO Open. 2022 Dec;7(6):100611. doi: 10.1016/j.esmoop.2022.100611. Epub 2022 Dec 1. ESMO Open. 2022. PMID: 36463731 Free PMC article.
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Kroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R, Nordsmark M, Pfeiffer P, Hawkins MA, Smyth E, Markar S, Hanna GB, Cheong E, Chaudry A, Elme A, Adenis A, Piessen G, Gani C, Bruns CJ, Moehler M, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, Jeene P, van Sandick JW, Muijs C, Slingerland M, Nieuwenhuijzen G, Wijnhoven B, Beerepoot LV, Kolodziejczyk P, Polkowski WP, Alsina M, Pera M, Kanonnikoff TF, Nilsson M, Guckenberger M, Monig S, Wagner D, Wyrwicz L, Berbee M, Gockel I, Lordick F, Griffiths EA, Verheij M, van Rossum PSN, van Laarhoven HWM; OMEC working group. Kroese TE, et al. Eur J Cancer. 2022 Mar;164:18-29. doi: 10.1016/j.ejca.2021.11.032. Epub 2022 Feb 5. Eur J Cancer. 2022. PMID: 35134666 Free article.
Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial.
Slagter AE, Vollebergh MA, Caspers IA, van Sandick JW, Sikorska K, Lind P, Nordsmark M, Putter H, Braak JPBM, Meershoek-Klein Kranenbarg E, van de Velde CJH, Jansen EPM, Cats A, van Laarhoven HWM, van Grieken NCT, Verheij M. Slagter AE, et al. Among authors: vollebergh ma. Gastric Cancer. 2022 Mar;25(2):401-410. doi: 10.1007/s10120-021-01258-6. Epub 2021 Oct 29. Gastric Cancer. 2022. PMID: 34714423 Free PMC article. Clinical Trial.
21 results